Form 4: Perceptive Advisors Reduces Lyra Therapeutics Stake

Perceptive Advisors and related entities, a 10% owner and director, reported multiple sales of Lyra Therapeutics common stock totaling 70,390 shares in early November 2025.

Summary

• Perceptive Advisors LLC, Perceptive Life Sciences Master Fund, Ltd., Perceptive LS (A), LLC, and Joseph Edelman, identified as 10% owners and directors of Lyra Therapeutics, Inc. (LYRA), reported multiple sales of common stock.
• A total of 70,390 shares of Lyra Therapeutics common stock were sold across three transaction dates: November 6, 7, and 10, 2025.
• On November 6, 2025, 28,902 shares were sold at a weighted average price of $5.1799 (ranging from $4.85 to $5.65), and an additional 3,247 shares were sold at the same price.
• On November 7, 2025, 17,746 shares were sold at a weighted average price of $4.7467 (ranging from $4.61 to $4.9), and an additional 1,993 shares were sold at the same price.
• On November 10, 2025, 16,633 shares were sold at a weighted average price of $4.5398 (ranging from $4.5 to $4.675), and an additional 1,869 shares were sold at the same price.
• Following these transactions, Perceptive Life Sciences Master Fund, Ltd. beneficially owns 166,101 shares, and Perceptive LS (A), LLC beneficially owns 18,659 shares.
• Joseph Edelman, as the managing member of Perceptive Advisors LLC and sole member of Perceptive LS GP, LLC, disclaims beneficial ownership of these securities except to the extent of his indirect pecuniary interest.

Sentiment

Score: 3

Explanation: The significant insider selling by a 10% owner and director, coupled with a declining average sale price over the transaction period, indicates a negative sentiment from a key institutional investor.

Negatives

• Significant insider selling by a 10% owner and director, which can signal a lack of confidence in the company's future prospects.
• The sales occurred over several days, with the weighted average sale price generally decreasing from $5.1799 to $4.5398, indicating a downward trend in the stock price during the selling period.
• A substantial reduction in the beneficial ownership stake by a key institutional investor.

Risks

• Potential negative market reaction to the insider selling, which could lead to a decrease in Lyra Therapeutics' share price.
• Reduced institutional investor confidence due to a major shareholder and director divesting a significant portion of their holdings.
• The declining average sale price during the transaction period suggests potential underlying concerns or a lack of positive catalysts for the stock.

Future Outlook

This filing does not contain any forward-looking statements or guidance from Lyra Therapeutics, Inc. It solely reports past insider transactions.

Management Comments

• Joseph Edelman, as the managing member of Perceptive Advisors LLC and the sole member of Perceptive LS GP, LLC, disclaims beneficial ownership of the reported securities, except to the extent of his indirect pecuniary interest therein.

Industry Context

Insider selling in the biotechnology sector, particularly by a major institutional investor with board representation, can be a strong indicator of perceived risks or limited upside potential for a company like Lyra Therapeutics. This type of activity often leads to increased scrutiny from other investors regarding the company's pipeline, clinical trial progress, or market position.

Related Party Transactions

• The reported transactions involve Perceptive Advisors LLC, Perceptive Life Sciences Master Fund Ltd, Perceptive LS (A), LLC, and Joseph Edelman, all of whom are related parties to Lyra Therapeutics as 10% owners and/or directors. These are direct sales of common stock by these related entities.

Stakeholder Impact

• Shareholders may perceive the insider selling as a lack of confidence in the company's future, potentially leading to a decrease in investor sentiment and share price.
• Other institutional investors might re-evaluate their positions in Lyra Therapeutics based on the actions of a significant holder and director.

Key Dates

Recommendation

The substantial insider selling by Perceptive Advisors, a 10% owner and director, suggests a lack of confidence in Lyra Therapeutics' current valuation or future prospects from a well-informed party. Such a move by a significant institutional investor often precedes further stock price declines or reflects concerns not yet fully public. Investors should consider reducing their exposure or avoiding new positions until there are clear positive catalysts or a reversal in insider sentiment.

Keywords

Lyra Therapeutics, LYRA, Perceptive Advisors, Insider Selling, Form 4, Beneficial Ownership, Stock Sale, Biotechnology, Healthcare Investment